InterMune’s Idiopathic Pulmonary Fibrosis Push Continues As Actimmune Sales Slump
This article was originally published in The Pink Sheet Daily
Executive Summary
Data support gambling on experimental pirfenidone against “incredibly complex” disease, chief scientific officer tells “The Pink Sheet” DAILY.